

Deriving personalised physical activity intensity thresholds by merging accelerometry with field-based walking tests: Implications for pulmonary rehabilitation

Chronic Respiratory Disease
Volume 19: 1–4
© The Author(s) 2022
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/14799731221129286
journals.sagepub.com/home/crd
 SAGE

Ilaria Pina^{1,2}, Pauline Ndagire³, Wincelous Katagira³, Lorna Latimer^{1,2},
Jakub Zatloukal², Bruce Kirenga³, Sally J Singh^{1,2} and Mark W Orme^{1,2}

Abstract

During pulmonary rehabilitation (PR), patients receive individually tailored walking exercise training. The personalised nature of exercise prescription is a fundamental component of PR. Despite this, the measurement of physical activity (PA) has been limited to a 'one size fits all' approach and can be challenging to translate into clinically meaningful or real-world units, such as cadence. This discrepancy may partly explain the inconsistent evidence for the impact of PR on PA. It may also provide an opportunity to standardise PA assessment in the context of chronic respiratory disease (CRD) and PR, where field-based walking tests are routine measures. This technical note provides an example of how to develop personalised PA intensity thresholds, calibrated against an individual's performance on the Incremental Shuttle Walking Test (ISWT; maximal) and Endurance Shuttle Walk Test (ESWT; sub-maximal). These are externally paced tests, with each level (speed) of the tests denoting a specific speed (intensity); ranging 1.8 km/h (ISWT Level 1) to 8.5 km/h (ISWT Level 12). From the ESWT, it becomes possible to evaluate adherence to each individual's walking exercise prescription. Future research should explore this approach and its responsiveness to PR. It may be possible to extend this methodology with the inclusion of physiological parameters (e.g., heart rate, calorimetry, and oxygen consumption) to derive relative intensity markers (e.g. moderate-to-vigorous), accounting for individual differences in exercise capacity, under the same paradigm as PR exercise prescription.

Keywords

accelerometry, device-based physical activity, endurance shuttle walking test, exercise capacity, incremental shuttle walking tests, accelerometer cut points

Date received: 1 June 2022; accepted: 24 August 2022

The measurement and evaluation of physical activity (PA) using accelerometers is commonplace in chronic respiratory diseases (CRD) research. Numerous studies have evaluated changes in PA following pulmonary rehabilitation (PR), with mixed results.^{1–4} Exercise is a sub-domain of PA and PR has personalised exercise training, therefore PA, at its core.⁵ However, less attention has been given to the

¹Department of Respiratory Sciences, University of Leicester, Leicester, UK

²Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory, University Hospitals of Leicester NHS Trust, Leicester, UK

³Makerere University Lung Institute, Kampala, Uganda

Corresponding author:

Ilaria Pina, Department of Respiratory Sciences, University of Leicester, Leicester LE1 7RH, UK.

Email: i.pina@leeds.ac.uk



Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (<https://creativecommons.org/licenses/by/4.0/>) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).

assessment of PA compared with exercise capacity. The Incremental Shuttle Walking Test (ISWT)⁶ and Endurance Shuttle Walk Test (ESWT)^{7,8} evaluate walking exercise capacity, allowing individualised walking exercise prescription and evaluation of change following PR. We propose an additional advantage to these tests; deriving personalised and real-world PA intensity thresholds.

The evaluation of accelerometry-derived free-living PA has been limited to ‘one-size-fits-all’ approaches, which do not account for individual differences in exercise capacity and can be challenging to translate into clinically meaningful units. This is demonstrated by the vast array of PA outcomes in the literature.^{9,10} In the same vein as personalised PA prescription during PR, it may be appropriate to ‘personalise’ PA intensity evaluation. By limiting the evaluation of PA to ‘one-size-fits-all’ thresholds risks making the data appear unresponsive to interventions, as a person’s potential to perform PA across intensities is inherently predicated on their physical capability. This is described previously through stratifying CRD populations by PA and exercise capacity.^{11,12} Studies examining this relationship in response to PR have shown that participants with higher baseline exercise capacity have greater PA response to PR than those with lower exercise capacity.^{2,13,14} The relationship between PA and exercise is strong, but this has not extended to merging these important constructs together.

By wearing accelerometers during field-based walking tests, it becomes possible to synchronise the assessment of PA and exercise capacity at the individual level. The ISWT and ESWT are measures of maximal and sub-maximal exercise capacity, respectively, used for the prescription of personalised walking exercise. The ISWT allows assessment across standardised levels denoting specific increasing externally paced speeds (intensity); ranging 1.8–8.53 km/h (Levels 1–12). By monitoring PA during these tests, it may be possible to generate easily interpretable personalised PA intensity thresholds with clear clinical application.

To illustrate the concept, we provide PA data of an individual living with post-tuberculosis lung disease, attending hospital-based PR in Uganda,¹⁵ performing ISWT and an ESWT wearing a waist-worn ActiGraph wGT3x-BT accelerometer (Figure 1).¹⁶ Data were obtained from an ongoing randomized controlled trial of PR for adults living with post-tuberculosis lung disease conducted at the Makerere University Lung Institute, Kampala, Uganda.¹⁵ The study received ethical approvals from the Mulago Hospital Research and Ethics Committee (MHREC1478), Kampala, Uganda and the Uganda National Council for Science and Technology (SS5105) and the University of Leicester (22349). For this technical note and for easy interpretation, cadence (steps/min) denotes PA intensity.¹² Panel-A shows individual cadences for each ISWT level.

The participant reached ISWT Level-6 (290 m), resulting in ESWT Level-9 (4.11 km/h) (Panel-B).⁷ Panel-C shows personalised cadence thresholds derived from ISWT and ESWT. In Panel-D, we can observe the time spent in free-living PA adjusted according to wear time and normalised for comparability, 7 days immediately pre- and post-PR, according to ISWT and ESWT thresholds. A consistent pattern of less time spent at greater PA intensities is seen. Following the completion of PR, the participant, based on pre-PR thresholds, displaced time in lower PA intensities with higher intensities (change of –9 min/day in PA pre-ISWT Level-1 and change of +34 min/day in PA above ISWT Level-1). Using the ESWT threshold, on average the participant spent 0 min/day in PA above the prescribed intensity (≥ 3.0 km/h) pre-PR and spent 5 min/day above their prescribed intensity post-PR.

We encourage future studies to explore this approach, as it adds minimal burden to the study team (e.g., no additional time for assessments needed) or participants (e.g., minimal burden wearing PA monitor during tests; similar to pulse oximeter). It is important to acknowledge that the cost of accelerometers and the additional time required for data processing remain broader practical challenges for implementation. It may be possible to extend this approach to commercial activity trackers, step-counting devices, and smart devices which people may already own or have access to.¹⁷ In our methodology, there appears to be a biomechanical influence due to an increase in step-width and stride variability between ISWT and ESWT thresholds, which may relate to the incremental versus steady-rate differences between the tests.¹⁸ Acknowledging the absence of traditional intensity thresholds (light, moderate, vigorous, very vigorous), we propose adding physiological data, such as heart rate, to derive these traditional thresholds at the individual level.

The key advantage of our proposal is its relevance to CRD populations, and other groups characterised by reduced exercise capacity, rather than using the current absolute intensity thresholds generated from healthier, younger populations with preserved exercise capacity. Whilst the ISWT and ESWT offer the most clinically relevant outputs with this new approach, it is possible to generate thresholds based on other common tests such as the six-minute walk test,¹⁹ but this will be more challenging to define due its self-paced nature. We have previously suggested integrating the use of PA monitors during field-based walking tests for quality assurance purposes,¹⁶ demonstrating further potential benefits of synchronising these methodologies. Indeed, the quality of the tests will dictate the quality (accuracy) of the resulting thresholds. Our approach, by synchronising PA assessment with the individual evaluation of exercise capacity in PR, could allow a more precise and responsive measure of changes in PA following an intervention such as PR.




Figure 1. Physical activity data (cadence) of an individual living with post-tuberculosis lung disease during ISWT and ESWT. Panel A: Cadence during each level of the individual's best ISWT. Panel B: Cadence during the ESWT (level 9; 4.11 km/h, 1.14 m/s). Panel C: Personalised physical activity intensity (cadence) thresholds derived from ESWT and each level of the ISWT. Dotted line at 100 step/min represents heuristic cadence threshold for moderate-to-vigorous physical activity.²⁰ Panel D: Pre and Post PR free-living time (adjusted for wear time) spent in PA above thresholds derived from each ISWT level and above their individually prescribed speed based on the ESWT. Abbreviations: PA: physical activity; PR: pulmonary rehabilitation; ISWT: incremental shuttle walking test; ESWT: endurance shuttle walk test.

In summary, we describe a new approach to deriving PA intensity thresholds, personalised to an individual's exercise capacity using field-based walking tests, which can offer a clinically meaningful and responsive methodology to assess PA changes following PR. In anticipation of the additional advantages of synchronising PA monitoring with field-based walking tests, PA as a routine outcome measure may become more feasible in research and clinical practice.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This

research was funded by the NIHR (17/63/20) using UK aid from the UK Government to support global health research.

Disclaimer

The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK government. Professor Singh is a NIHR Senior Investigator. The views expressed in this article are those of the author(s) and not necessarily those of the NIHR, or the Department of Health and Social Care.

ORCID iDs

Ilaria Pina <https://orcid.org/0000-0002-6294-5398>
 Wincelous Katagira <https://orcid.org/0000-0003-4622-191X>
 Lorna Latimer <https://orcid.org/0000-0003-3561-438X>
 Jakub Zatloukal <https://orcid.org/0000-0001-9000-4707>
 Bruce Kirenga <https://orcid.org/0000-0002-2023-2840>
 Sally J Singh <https://orcid.org/0000-0002-9834-0366>
 Mark W Orme <https://orcid.org/0000-0003-4678-6574>

References

1. Mesquita R, Meijer K, Pitta F, et al. Changes in physical activity and sedentary behaviour following pulmonary rehabilitation in patients with COPD. *Respir Med* 2017; 126: 122–129.
2. Osadnik CR, Loeckx M, Louvaris Z, et al. The likelihood of improving physical activity after pulmonary rehabilitation is increased in patients with COPD who have better exercise tolerance. *Int J Chron Obstruct Pulmon Dis* 2018; 13: 3515–3527.
3. Spruit MA, Pitta F, McAuley E, et al. Pulmonary rehabilitation and physical activity in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2015; 192: 924–933.
4. Blondeel A, Demeyer H, Janssens W, et al. The role of physical activity in the context of pulmonary rehabilitation. *COPD: J Chron Obstruct Pulmon Dis* 2018; 15: 632–639.
5. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. *Am J Respir Crit Care Med* 2013; 188: e13–e64.
6. Singh SJ, Morgan M, Scott S, et al. Development of a shuttle walking test of disability in patients with chronic airways obstruction. *Thorax* 1992; 47: 1019–1024.
7. Revill S, Morgan M, Singh S, et al. The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. *Thorax* 1999; 54: 213–222.
8. Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. *Eur Respir J* 2014; 44: 1428–1446.
9. Byrom B and Rowe DA. Measuring free-living physical activity in COPD patients: deriving methodology standards for clinical trials through a review of research studies. *Contemp Clin Trials* 2016; 47: 172–184.
10. Jayamaha AR, Jones AV, Katagira W, et al. Systematic review of physical activity, sedentary behaviour and sleep among adults living with chronic respiratory disease in low-and middle-income countries. *Int J Chron Obstruct Pulmon Dis* 2022; 17: 821–854.
11. Singh S. *Physical activity and pulmonary rehabilitation—A competing agenda?* London, UK: SAGE Publications, 2014, pp. 187–189.
12. Koolen EH, van Hees HW, van Lummel RC, et al. Can do” versus “do do”: a novel concept to better understand physical functioning in patients with chronic obstructive pulmonary disease. *J Clin Med* 2019; 8: 340.
13. Gulart AA, Munari AB, Silva IJCS, et al. Baseline characteristics associated to improvement of patients with COPD in physical activity in daily life level after pulmonary rehabilitation. *Respir Med* 2019; 151: 142–147.
14. Rochester CL. Patient assessment and selection for pulmonary rehabilitation. *Respirology* 2019; 24: 844–853.
15. Katagira W, Orme MW, Jones AV, et al. Study protocol for a randomised controlled trial assessing the impact of pulmonary rehabilitation on maximal exercise capacity for adults living with post-TB lung disease: global RECHARGE Uganda. *BMJ Open* 2021; 11: e047641.
16. Orme MW, Pina I and Singh SJ. The untapped potential of physical activity monitoring for quality assurance of field-based walking tests in clinical respiratory trials. *Chron Respir Dis* 2022; 19: 14799731221089318.
17. Ward S, Orme M, Zatloukal J, et al. Adherence to walking exercise prescription during pulmonary rehabilitation in COPD with a commercial activity monitor: a feasibility trial. *BMC Pulmon Med* 2021; 21: 1–9.
18. Jordan K, Challis JH and Newell KM. Walking speed influences on gait cycle variability. *Gait Posture* 2007; 26: 128–134.
19. Burioka N, Imada A, Kiyohiro A, et al. Modified six-minute walk test: number of steps per second. *Yonago Acta Medica* 2014; 57: 61–63.
20. Tudor-Locke C, Ducharme SW, Aguiar EJ, et al. Walking cadence (steps/min) and intensity in 41 to 60-year-old adults: the CADENCE-adults study. *Int J Behav Nutr Phys Activity* 2020; 17: 1–10.